In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and ...

Mounjaro, manufactured by US drugmaker, and Wegovy by Danish drugmaker Novo Nordisk, cause weight loss by suppressing the ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

Mounjaro has been found to be more effective than Wegovy in the first direct comparison trial of two major weight-loss drugs.